GlobeNewswire

Victor Alvarado named SVP, Operations and Engineering, NOVA Chemicals

Share

Calgary, Alberta, Canada , June 10, 2021 (GLOBE NEWSWIRE) -- NOVA Chemicals Corporation (“NOVA Chemicals”) today announced Victor Alvarado will join the Company on July 1 as Senior Vice President, Operations and Engineering.

Alvarado will be responsible for the safe, reliable and competitive operations of the company’s manufacturing facilities and its support functions. Reporting to Luis Sierra, President & Chief Executive Officer, he will become a member of NOVA’s senior executive committee and will be based in Calgary, AB. With over 30 years’ global manufacturing experience, Alvarado will play a pivotal role in the safe and successful completion of the company’s significant growth investments in Sarnia, ON, while providing strategic leadership to ensure world-class competitiveness of NOVA’s manufacturing assets.

“Victor is a very experienced and well-respected global petrochemicals executive with a proven track record of leading manufacturing organizations to higher levels of reliability and turnaround performance in the US, Europe and Asia,” stated Sierra. “His experience and insight will be a tremendous asset to NOVA as we continue to position the company as a leading low-carbon player in the olefins and polymers industry,” continued Sierra.

“NOVA has a strong reputation as a responsible plastics producer with a commitment to safety, our communities and the environment. I’m excited to join such a talented team and look forward to the opportunity to continue building upon that proud history,” stated Alvarado.

A graduate of the University of Illinois with a degree in Chemical Engineering, Alvarado rose through the ranks at BP and its predecessor company, Amoco, in various engineering, operations and commercial roles, culminating as Vice President of Global Aromatics, before being named as Operations Director, Global Aromatics at INEOS.

##

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

RESULT OF RIKSBANK REVERSED AUCTIONS SEK MUNICIPAL BONDS15.6.2021 11:30:00 CEST | Press release

AuctionAuction resultsAuction date2021-06-15Maturity2024Tendered volume, SEK mln1000 +/- 1000Offered volume, SEK mln137Volume bought, SEK mln137Number of bids3Number of accepted bids3 QuarterQuarter 1Quarter 2Quarter 3Quarter 4Offered volume, SEK mln0000Volume bought, SEK mln0000Number of bids0000Number of accepted bids0000Average DM----Lowest accepted DM----Highest DM----Accepted at lowest DM---- QuarterQuarter 1Quarter 2Quarter 3Quarter 4Offered volume, SEK mln013070Volume bought, SEK mln013070Number of bids0210Number of accepted bids0210Average DM--5-2-Lowest accepted DM--5-2-Highest DM--5-2-Accepted at lowest DM-100.00%100.00%-

Karolinska Development’s portfolio company Modus Therapeutics and Imperial College London to conduct clinical study of sevuparin in severe malaria15.6.2021 11:24:44 CEST | Press release

STOCKHOLM, SWEDEN – June 15, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Modus Therapeutics has entered into a collaboration agreement with Imperial College London to evaluate the effect of its drug candidate sevuparin in patients with severe malaria. Sevuparin is currently being developed in the indication sepsis/septic shock, a condition that bears resemblance to the systemic inflammatory reaction that occurs in connection with severe malaria infection. Malaria causes more than 400,000 deaths per year and the need for new and effective drugs is therefore great. Severe malaria continues to be a medical challenge in several parts of the world. The disease often affects children and the need for effective drugs is great as malaria can induce a systemic inflammatory reaction leading to multi-organ failure, a reaction similar to that seen in sepsis/septic shock. The purpose of the collaboration announced today is to conduct a clinica

Karolinska Developments portföljbolag Modus Therapeutics och Imperial College London planerar klinisk studie av sevuparin mot svår malaria15.6.2021 11:24:44 CEST | Pressemelding

STOCKHOLM, SVERIGE 15 juni 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Modus Therapeutics och Imperial College London har ingått ett samarbetsavtal i syfte att utvärdera effekten av bolagets läkemedelskandidat sevuparin i patienter med svår malaria. Sevuparin utvecklas sedan tidigare inom indikationen sepsis/septisk chock, ett tillstånd som bär vissa likheter med den systemiska inflammationsreaktion som uppstår i samband med svår malariainfektion. Malaria orsakar fler än 400 000 dödsfall per år och behovet av nya och effektiva läkemedel är därför stort. Svår malaria utgör fortsatt en medicinsk utmaning i flera delar av världen. Sjukdomen drabbar ofta barn och behovet av effektiva läkemedel är stort eftersom malaria kan inducera en systemisk inflammatorisk reaktion som leder till multiorgansvikt, en reaktion som liknar den man ser vid sepsis/septisk chock. Syftet med det samarbete som annonseras idag är att genomföra en klinisk studie för a

CONDITIONS FOR SALE OF RIKSBANK CERTIFICATES15.6.2021 09:30:00 CEST | Press release

Bid date, 2021-06-15Auction date2021-06-15Settlement date2021-06-16Maturity Date2021-06-23Nominal amount484 billion SEKInterest rate, %0.00Bid times09.30-10.00 (CET/CEST) on the Bid dateConfirmation of bids to e-mailrbcert@riksbank.seThe lowest accepted bid volume1 million SEKThe highest accepted bid volume484 billion SEKAllocation Time10.15 (CET/CEST) on the Bid dateProjected minimum liquidity surplus during the term968 billion SEKExpected excess liquidity at full allotment484 billion SEK Stockholm, 2021-06-15

Klövern kommer att sammankalla en extra bolagsstämma enligt begäran från Corem15.6.2021 09:06:03 CEST | Pressemelding

En extra bolagsstämma kommer att hållas i Klövern AB (publ) (”Klövern”) den 9 juli 2021 för val av ny styrelse i enlighet med begäran från Corem. Kallelse utfärdas separat. Corem Property Group AB (publ) (”Corem”) lämnade den 29 mars 2021 ett offentligt uppköpserbjudande till aktieägarna i Klövern. Corem förklarade idag erbjudandet ovillkorat och förlängde acceptfristen till den 23 juni 2021. Corem kontrollerar cirka 89,1 procent av de utestående aktierna och cirka 90,8 procent av rösterna i Klövern. Klövern AB (publ) För ytterligare information, vänligen kontakta: Pia Gideon, styrelseordförande i Klövern Tel: 070-546 71 00 Klövern är ett fastighetsbolag som med närhet och engagemang erbjuder attraktiva lokaler i tillväxtregioner. Klövern är noterat på Nasdaq Stockholm. Ytterligare information finns på www.klovern.se. Klövern AB (publ), Bredgränd 4, 111 30 Stockholm. Tel: 010-482 70 00, Email: info@klovern.se. Detta pressmeddelande har offentliggjorts på svenska och engelska. Vid en ev

Klövern will convene an Extraordinary General Meeting in accordance with a request from Corem15.6.2021 09:06:03 CEST | Press release

An Extraordinary General Meeting will be held in Klövern AB (publ) (”Klövern”) on 9 July 2021 to elect a new Board of Directors in accordance with a request from Corem. A notice will be issued separately. On 29 March 2021, Corem Property Group AB (publ) (”Corem”) announced a public offer to the shareholders of Klövern. Today, Corem declared the offer unconditional and extended the acceptance period to 23 June 2021. Corem controls approximately 89.1 percent of the outstanding shares and approximately 90.8 percent of the votes in Klövern. Klövern AB (publ) For further information, pleasecontact: Pia Gideon, Chairman of the Board of Directors in Klövern Phone: +46 70 546 71 00 Klövern is a real estate company committed to working closely with customers to offer them attractive premises in growth regions. Klövern is listed on Nasdaq Stockholm. For further information, see www.klovern.se. Klövern AB (publ), Bredgränd 4, 111 30 Stockholm. Phone: +46 10 482 70 00. Email: info@klovern.se. This